MedTrace Logo

Role of Anti-IgE in Severe Childhood Eczema

NCT02300701 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2019-08-09

No results posted yet for this study

Summary

To evaluate the efficacy of anti-IgE (Omalizumab/Xolair) in children with severe eczema.

Conditions

Interventions

DRUG

Xolair

According to manufacturer's instructions

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • King's College London

    collaborator OTHER

  • National Institute for Health Research, United Kingdom

    collaborator OTHER_GOV

  • Guy's and St Thomas' NHS Foundation Trust

    lead OTHER

Principal Investigators

  • S Chan, MBBS, MD · Guy's and St Thomas' Hospitals NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2018-08-31
Completion
2018-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02300701 on ClinicalTrials.gov